HK1123495A1 - Methods of protecting against apoptosis using lipopeptides - Google Patents

Methods of protecting against apoptosis using lipopeptides

Info

Publication number
HK1123495A1
HK1123495A1 HK09100988A HK09100988A HK1123495A1 HK 1123495 A1 HK1123495 A1 HK 1123495A1 HK 09100988 A HK09100988 A HK 09100988A HK 09100988 A HK09100988 A HK 09100988A HK 1123495 A1 HK1123495 A1 HK 1123495A1
Authority
HK
Hong Kong
Prior art keywords
lipopeptides
methods
protecting against
against apoptosis
apoptosis
Prior art date
Application number
HK09100988A
Other languages
English (en)
Inventor
Alexander N Shakhov
Andrei Gudkov
Original Assignee
Cleveland Biolabs Inc
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Biolabs Inc, Cleveland Clinic Foundation filed Critical Cleveland Biolabs Inc
Publication of HK1123495A1 publication Critical patent/HK1123495A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK09100988A 2005-06-13 2009-02-04 Methods of protecting against apoptosis using lipopeptides HK1123495A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68981005P 2005-06-13 2005-06-13
PCT/US2006/022865 WO2006138238A2 (en) 2005-06-13 2006-06-13 Methods of protecting against apoptosis using lipopeptides

Publications (1)

Publication Number Publication Date
HK1123495A1 true HK1123495A1 (en) 2009-06-19

Family

ID=37571018

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09100988A HK1123495A1 (en) 2005-06-13 2009-02-04 Methods of protecting against apoptosis using lipopeptides
HK13109211.9A HK1181684A1 (en) 2005-06-13 2013-08-06 Methods of protecting against apoptosis using lipopeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK13109211.9A HK1181684A1 (en) 2005-06-13 2013-08-06 Methods of protecting against apoptosis using lipopeptides

Country Status (17)

Country Link
US (4) US8008260B2 (de)
EP (2) EP1904084B1 (de)
JP (1) JP5000644B2 (de)
KR (2) KR101604799B1 (de)
CN (1) CN101242852B (de)
AU (1) AU2006259630B2 (de)
BR (1) BRPI0611586A2 (de)
CA (1) CA2612102C (de)
EA (1) EA014644B1 (de)
ES (2) ES2539490T3 (de)
HK (2) HK1123495A1 (de)
IL (1) IL188091A (de)
MX (1) MX2007015834A (de)
NZ (1) NZ565063A (de)
PT (1) PT1904084E (de)
WO (1) WO2006138238A2 (de)
ZA (1) ZA200800126B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457070B2 (en) 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
WO2006133403A2 (en) 2005-06-07 2006-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
BRPI0611586A2 (pt) 2005-06-13 2010-09-21 Cleveland Biolabs Inc métodos de proteção contra apoptose mediante uso de lipopeptìdeos
US8216582B2 (en) * 2006-06-23 2012-07-10 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
CA2675032A1 (en) * 2007-01-09 2008-07-17 Cleveland Biolabs, Inc. Methods for increasing and mobilizing hematopoietic stem cells
WO2009074569A1 (en) * 2007-12-11 2009-06-18 Bracco International Bv Targeting and therapeutic compounds with a polyproline-comprising spacer and gas-filled microvesicles comprising said compounds
US9150621B2 (en) * 2008-08-28 2015-10-06 The University Of Queensland Mutant bacterial glycoproteins and uses thereof
AU2009293750C1 (en) * 2008-09-18 2016-02-04 Nippon Zoki Pharmaceutical Co., Ltd. Amino acid derivative
MX336869B (es) 2008-11-03 2016-02-04 Alethia Biotherapeutics Inc Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
US8404444B2 (en) * 2009-02-25 2013-03-26 Diacarta Llc Method for predicting the level of damage to cells by measuring free circulating Alu nucleic acid
JP5210405B2 (ja) * 2010-03-17 2013-06-12 日本臓器製薬株式会社 アミノ酸誘導体を含有する医薬及び該誘導体の製造方法
EP2490021A1 (de) 2011-02-18 2012-08-22 Biotempt B.V. Modulatoren von PRR- und GPCR-Signalisierung
US8980574B2 (en) 2011-03-11 2015-03-17 James D. Crapo Method for ameliorating radiation exposure effects with alpha-1 antitrypsin
PL3173427T3 (pl) 2011-03-31 2019-11-29 Adc Therapeutics Sa Przeciwciała przeciwko antygenowi związanemu z nerkami 1 i ich fragmenty wiążące antygen
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
PT2802351T (pt) 2012-01-09 2019-06-27 Adc Therapeutics Sa Agentes para o tratamento de cancro da mama triplo negativo
JP5686841B2 (ja) * 2013-04-26 2015-03-18 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 損傷しまたは傷害を受けた組織または臓器の内皮／上皮再生用医薬の製造のための、幹細胞由来微小胞（ｍｖ）の使用ならびにインビトロおよびインビボでの関連した方法
US20160287553A1 (en) 2013-11-22 2016-10-06 Deutsches Krebsforschungszentrum Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
WO2016073733A1 (en) * 2014-11-06 2016-05-12 Cleveland Biolabs, Inc. Methods of treating cancer using lipopeptides
CN112851755B (zh) * 2021-01-13 2023-09-01 中国人民解放军军事科学院军事医学研究院 一种线性脂肽化合物及其制备方法与应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2860893D1 (en) 1977-06-20 1981-11-05 Ciba Geigy Ag Lipopeptides, process for their preparation and pharmaceutical compositions containing them
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
AU666789B2 (en) * 1992-12-28 1996-02-22 Takeda Chemical Industries Ltd. 2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
EP0604945A1 (de) 1992-12-28 1994-07-06 Takeda Chemical Industries, Ltd. TAN-1511, Derivate, Herstellung und Verwendung
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
AU1170595A (en) 1993-11-04 1995-05-23 Cytoclonal Pharmaceutics, Inc. A fusion protein and method for making and using same
WO1999035162A1 (en) * 1998-01-07 1999-07-15 Jenner Biotherapies, Inc. Therapeutic liposome-encapsulated immunomodulators
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
DE19822820A1 (de) 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung
US20030170249A1 (en) * 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
WO2000064439A1 (en) * 1999-04-26 2000-11-02 Center For Molecular Medicine And Immunology Use of antioxidants to mitigate radioimmunotherapy-induced radiation toxicity
AU4134901A (en) * 1999-10-27 2001-05-30 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
DE10048840A1 (de) * 2000-10-02 2002-04-11 Biotechnolog Forschung Gmbh Verwendung von Lipopeptiden oder Lipoproteinen zur Behandlung von Lungeninfektionen und -tumoren
SI1411918T1 (sl) 2001-07-31 2012-04-30 Genzyme Global S A R L Postopki za mobilizacijo progenitorskih/matičnih celic
DE50309916D1 (de) 2002-04-04 2008-07-10 Helmholtz Infektionsforschung Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
US20040259790A1 (en) * 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
WO2005030133A2 (en) * 2003-09-22 2005-04-07 Yale University Treatment with agonists of toll-like receptors
UA83272C2 (uk) 2003-12-02 2008-06-25 Клевеленд Клінік Фаундейшн Спосіб захисту від ефектів іонізуючого випромінювання за допомогою флагеліну
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
US20060039895A1 (en) * 2004-02-28 2006-02-23 Large Scale Biology Corporation Ex-vivo rescue of hematopoietic stem cells after lethal irradiation
BRPI0611586A2 (pt) * 2005-06-13 2010-09-21 Cleveland Biolabs Inc métodos de proteção contra apoptose mediante uso de lipopeptìdeos
CA2675032A1 (en) 2007-01-09 2008-07-17 Cleveland Biolabs, Inc. Methods for increasing and mobilizing hematopoietic stem cells

Also Published As

Publication number Publication date
CN101242852A (zh) 2008-08-13
EP1904084B1 (de) 2013-04-24
ZA200800126B (en) 2009-10-28
CA2612102A1 (en) 2006-12-28
AU2006259630B2 (en) 2011-10-27
US9006183B2 (en) 2015-04-14
WO2006138238A3 (en) 2007-07-19
IL188091A0 (en) 2008-03-20
US8524668B2 (en) 2013-09-03
KR101604799B1 (ko) 2016-03-28
ES2539490T3 (es) 2015-07-01
CA2612102C (en) 2016-02-09
EP1904084A4 (de) 2012-03-21
KR20080030566A (ko) 2008-04-04
HK1181684A1 (en) 2013-11-15
US20110237507A1 (en) 2011-09-29
EP1904084A2 (de) 2008-04-02
NZ565063A (en) 2011-04-29
IL188091A (en) 2014-06-30
EA200702510A1 (ru) 2008-06-30
KR20140041874A (ko) 2014-04-04
EP2554181B1 (de) 2015-03-18
JP2008543847A (ja) 2008-12-04
JP5000644B2 (ja) 2012-08-15
PT1904084E (pt) 2013-07-22
ES2421447T3 (es) 2013-09-02
MX2007015834A (es) 2008-09-15
CN101242852B (zh) 2012-10-10
US9381225B2 (en) 2016-07-05
US20150306168A1 (en) 2015-10-29
AU2006259630A1 (en) 2006-12-28
BRPI0611586A2 (pt) 2010-09-21
WO2006138238A2 (en) 2006-12-28
EP2554181A3 (de) 2013-03-13
EA014644B1 (ru) 2010-12-30
EP2554181A2 (de) 2013-02-06
US20140045750A1 (en) 2014-02-13
US20090214467A1 (en) 2009-08-27
US8008260B2 (en) 2011-08-30

Similar Documents

Publication Publication Date Title
HK1181684A1 (en) Methods of protecting against apoptosis using lipopeptides
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
AP2870A (en) Odcase inhibitors for the treatment of malaria
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
EP1874731A4 (de) Chinobenzoxazinanaloga und verfahren zu deren anwendung
IL185757A0 (en) Methods of decreasing calcifcation
HK1161122A1 (en) Use of 24-norudca 24-norudca
HK1104093A1 (en) Lockable push-piece
GB2439242B (en) Protection sleeve
ZA200902300B (en) Use of modified cyclosporins
EP1890761A4 (de) Verfahren zur verstärkung der lipolyse
ZA200709674B (en) Use of prochloraz for wood protection
GB0603513D0 (en) Protecting sleepsuit
EP1931370A4 (de) Verwendung von des-aspartat-angiotensin i
IL194798A0 (en) Treatment of melanoma
GB0510013D0 (en) Interaction of SNEV
GB0517792D0 (en) Instrument protection
GB0509544D0 (en) Shower protected airer
HU0500461D0 (en) Pyperazinyl derivatives of alkyl-oxindoles
HU0500175V0 (en) Assembly for protecting of mattress
GB0512574D0 (en) Uses of (s)-clenbuterol
AU2005906584A0 (en) Use of Inhibitors of Prolyl-4-Hydroxylases
ZA200710971B (en) Elasmobranch-repelling compounds and methods of use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170613